GlassScriptPhysician profile
William D Jones
NPI 1669481537
$1,990.70
in general payments reported to CMS, 2019-2025
23 companies · $378 in 2025
The $378 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $241 · 2021: $142 · 2022: $227 · 2023: $279 · 2024: $343 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $999.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $357.49 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Novo Nordisk INC | $344.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $177.56 | 2021-2025 | |
| Pfizer INC. | $135.27 | 2019-2021 | |
| Abbott Laboratories | $134.65 | 2021-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $116.07 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.80 | 2019-2025 | Jardiance |
| Allergan, INC. | $103.46 | 2019-2020 | |
| Lilly USA, LLC | $76.80 | 2022-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $69.54 | 2019-2023 | Breztri, Farxiga |
| Xeris Pharmaceuticals, INC. | $67.00 | 2023 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $63.64 | 2022-2025 | Arexvy, Shingrix |
| Baxter Healthcare | $33.23 | 2025 | Artiss |
| Astellas Pharma US INC | $31.26 | 2019-2024 | Veozah |
| Shire North American Group INC | $28.61 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ossur Americas, INC. | $21.36 | 2025 | |
| Ibsa Pharma INC. | $20.43 | 2023 | Tirosint, Licart |
| Exact Sciences Corporation | $19.43 | 2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.23 | 2025 | Xifaxan |
| Ironwood Pharmaceuticals, INC | $17.99 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.67 | 2022 | |
| Avanos Medical | $15.54 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.